Media coverage about Codexis (NASDAQ:CDXS) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Codexis earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.0117411860758 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s analysis:
- Codexis And Nestle Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership (thestreet.com)
- Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership (finance.yahoo.com)
- ETFs with exposure to Codexis, Inc. : October 12, 2017 (finance.yahoo.com)
- Codexis, Inc. :CDXS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 11, 2017 (finance.yahoo.com)
- Codexis, Inc. (CDXS) Upgraded to Hold by Zacks Investment Research (americanbankingnews.com)
Codexis (NASDAQ:CDXS) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $10.30 million for the quarter, compared to the consensus estimate of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. The firm’s quarterly revenue was down 35.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.12 EPS.
Several equities research analysts recently issued reports on the stock. HC Wainwright set a $8.00 target price on shares of Codexis and gave the stock a “buy” rating in a research report on Friday, August 11th. BidaskClub raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Jefferies Group LLC reissued a “buy” rating and issued a $9.00 target price (up from $8.00) on shares of Codexis in a research report on Monday, October 2nd. Zacks Investment Research cut shares of Codexis from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Finally, ValuEngine raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $7.00.
TRADEMARK VIOLATION NOTICE: “Codexis (CDXS) Earns Media Impact Score of 0.24” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/2956835/codexis-cdxs-earns-media-impact-score-of-0-24.html.
In other news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $5.78, for a total value of $6,126,800.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 9.80% of the stock is owned by corporate insiders.
Codexis Company Profile
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.